Imatinib and beyond in gastrointestinal stromal tumors: A radiologist's perspective.
OBJECTIVE
The purpose of this article is to review the decade-long experience with imatinib and other molecular targeted agents in the treatment of gastrointestinal stromal tumor (GIST).


CONCLUSIONS
Tremendous progress has been made in the medical management of GIST since the inception of imatinib, and imaging has played a key role in understanding the typical and atypical responses of GIST to molecular targeted therapies.
1 Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
Sree Harsha
SH
Tirumani
Jyothi P
JP
Jagannathan
Katherine M
KM
Krajewski
Atul B
AB
Shinagare
Heather
H
Jacene
Nikhil H
NH
Ramaiya
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use*; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis*; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging / Q000379:methods*; D010879:Piperazines / Q000627:therapeutic use*; D049268:Positron-Emission Tomography; D011743:Pyrimidines / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate